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Abstract
Purpose Thermoresponsive hydrogels are gels which have
different properties at varying temperatures. The objective
of this study was to assess the material characteristics,
imaging properties and chemotherapeutic drug release
profile of a novel radiopaque thermoresponsive hydrogel
in vitro, which is liquid at room temperature but solidifies
at body temperature, to determine potential suitability for
intratumoural delivery.
Materials and Methods An iodinated radiopaque thermoresponsive hydrogel was formulated using iodixanol at a
range of concentrations and assessed for sol–gel transition,
radiopacity and imaging using CT and US. A lead formulation containing iodixanol at a concentration of 9.22%
weight by weight (w/w, g of iodixanol per g of hydrogel)
was evaluated in vitro for injectability, disintegration and
dual drug release of cisplatin and paclitaxel from the
hydrogel formulation.
Results Radiopacity of the hydrogel increased in a concentration-dependent manner, but the highest concentration
of iodixanol evaluated in this study (13.83% w/w)
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adversely affected the sol–gel transition of the hydrogel;
therefore, 9.22% w/w iodixanol hydrogel was identified as
the lead formulation. This formulation was readily visible
on both CT and US. The formulation was hand
injectable through a range of clinically relevant devices,
had a sustained disintegration profile for up to 28 days and
was able to deliver a sustained release of chemotherapeutic
drug for up to 10 days.
Conclusions Favourable in vitro and ex vivo imaging and
material characteristics of this thermoresponsive gel are
demonstrated, suggesting potential interventional oncology
applications for image-guided intratumoural delivery of
sustained-release chemotherapy.
Keywords Thermoresponsive hydrogel  Intratumoural
injection  Radiopaque  Chemotherapy

Introduction
Systemic chemotherapy, in conjunction with radiation and
surgery, has long been the mainstay of cancer treatment.
Lack of chemotherapy specificity, toxicity, off-target side
effects and poor penetration into the tumour mass due to
the altered tumour microenvironment limits efficacy, which
has encouraged alternative delivery methods to be investigated [1–4]. One such approach is direct injection of
chemotherapeutics into the tumour, delivering chemotherapeutics or other ablative agents directly to achieve high
local concentrations while reducing systemic toxicity.
In vivo animal studies have shown that direct intratumoural
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instillation of a chemotherapeutic solution can deliver more
than 10–30 times intravenous doses, with minimal side
effects [5]. Intratumoural chemotherapy has also been
explored clinically, with promising safety and proof of
concept data generated [6–8]. Direct intratumoural instillation is, however, limited by rapid solution clearance from
the tumour site, resulting in inaccurate and unpredictable dosing. Therefore, attention has turned to the
development of drug delivery systems which can facilitate
delivery and retention at the site of action, and sustained
intratumoural release of chemotherapeutics [4].
Thermoresponsive hydrogels offer the possibility of an
injectable liquid at room temperature that can phase transition to a semi-solid hydrogel at physiological temperatures and have been investigated in pre-clinical and clinical
settings for intratumoural drug delivery in solid tumours
[9, 10]. This is an attractive drug delivery platform, due to
the potential for image-guided administration without the
need for surgical implantation of hardware. In situ gelation
permits hydrogels to mould to the target tissue, facilitating
a better fit than preformed implants [11], and facilitates
sustained release of the drug at the required site of action
[12–14]. Hydrogels can also be disintegrable, and the rate
of disintegration can be tailored without the need for surgical removal.
Only a handful of thermoresponsive hydrogels have
progressed to clinical trials, with varying degrees of success [4, 15–19]. This lack of clinical translation may be due
to the fact that whilst the studied gelling properties are of
importance, other factors which are of clinical relevance
such as visibility using image guidance, injectability,
hydrogel distribution, drug release, retention and disintegration have not been given sufficient consideration during
development. This study explores these clinically relevant
factors of a novel thermoresponsive hydrogel formulation
that has been specifically developed for intratumoural
delivery.

Methods
Formulation of a Radiopaque Thermoresponsive
Hydrogel With and Without Chemotherapeutic
Drug Loading
A novel proprietary thermoresponsive hydrogel developed
in a university research laboratory was prepared with a
commercially available iodinated contrast agent iodixanol
(Visipaque 320 mg I/ml, GE Healthcare, IL, USA).
Iodixanol was added at concentrations of 0% w/w, 4.61%
w/w, 9.22% w/w or 13.83% w/w, based on previous work
carried out by Fatimi [19]. A dual drug-loaded version of
this radiopaque thermoresponsive hydrogel was prepared
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using two widely used chemotherapeutic agents, cisplatin
and paclitaxel. Cisplatin was loaded into the aqueous phase
of the thermoresponsive hydrogel with stirring. Solubilisation of paclitaxel in a formulation excipient was undertaken prior to drug loading into the thermoresponsive
hydrogel.
Assessment of Material Characteristics of IodixanolLabelled Hydrogel Formulation
The thermoresponsivity and shear thinning properties of
the hydrogel formulations were assessed using oscillatory
and flow measurements, performed on a constant stress
rheometer (AR-1000, TA instruments, Delaware, USA).
The rheometer was equipped with cone/plate geometry
(40 mm diameter, 4 cone angle). Degassed samples were
dispensed onto the temperature controlled rheometer plate,
pre-equilibrated to 20 C and covered with a solvent trap
during testing. Oscillatory temperature sweeps from 20 to
40 C were performed to determine sol–gel transition
temperatures. The viscosity properties of the thermoresponsive hydrogel in response to an applied shear stress
were also investigated in order to predict the material
behaviour during injection. In response to an increasing
shear stress applied shear thinning materials will decrease
viscosity, while shear thickening materials will increase
viscosity. Shear thinning materials are, therefore, the most
suitable for injection purposes as the decreasing viscosity
of the injectate will facilitate easier injection. Shear thinning properties of hydrogel formulations were assessed at
20 C under increasing shear stress from 1 to 100 Pa. All
experiments were repeated in triplicate. Data were processed using TA Data Analysis software.
Measurement of Radiopacity of Iodixanol-Labelled
Hydrogel Formulation
2 ml of iodixanol-labelled hydrogel formulation was added
per well in a 12-well plate. Radiopacity was determined
using a commercially available computed tomography
(CT) machine (Ingenuity Core 128, Philips Healthcare,
Best, The Netherlands). Spiral volumetric acquisition
through each 12-well plate was obtained using 0.8 mm
slice thickness, 0.4 mm reconstruction interval, 168 mA s
and 100 kV. A region of interest (10 mm diameter) was
positioned centrally within each well on a coronal reformat
for acquisition of density measurements, ensuring only
hydrogel was included within the region of interest,
excluding both air and plate. The average density was
calculated (minimum, maximum and standard deviation
also recorded). All measurements were carried out in
triplicate. Data shown are represented as the mean ± standard error of the mean (SEM) (n = 3).
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Assessment of Distribution of Iodixanol-Labelled
Hydrogel in Ex Vivo Animal Tissue
Ex vivo tissue (calves liver) was used to assess the distribution of injected radiopaque thermoresponsive hydrogel.
Prior to injection, the ex vivo tissue was heated to 37 C in
a water bath. Internal tissue temperature was recorded
using a tissue thermometer. 5 ml of hydrogel with 9.22%
w/w iodixanol was injected into the ex vivo tissue model
using an 18 G 5 cm vascular access needle (Cook Medical,
IN, USA) at a constant rate to assess distribution of injected
thermoresponsive hydrogel in tissue. Three injections were
made. Administration was monitored using a commercially
available 12 MHz linear ultrasound (US) probe (Xario,
Toshiba, Tokyo, Japan) in grayscale B-mode. Ex vivo
distribution post-injection was imaged using CT as outlined previously.
Assessment of Injectability of Hydrogel Formulation
Uniaxial tensile testing was carried out to determine the
force required to expel hydrogels from a syringe fitted with
a needle or catheter, using a mechanical testing machine
(Z050, Zwick/Roell, Ulm, Germany), fitted with a 5-kN
load cell (Fig. 1). Samples were loaded into 2 ml Leurlok syringes, and the required medical device was
attached to the syringe via Luer-lok (Table 1). A preload
of 1 N was applied, and the end of test was determined to
be the maximum extension (8.5 mm); the distance equivalent to 0.5 ml of hydrogel (measured using Vernier
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callipers). The speed of injection was defined as 2 ml/min,
and the solution expelled from the catheter was collected in
a vial. All measurements were carried out in a minimum of
triplicate. Results are represented as the mean ± SEM
(n = minimum of 3).
Disintegration Studies
1 g of the radiopaque thermoresponsive hydrogel formulation (blank or drug-loaded) containing 9.22% w/w
iodixanol was added to a glass vial and submerged in a
shaking water bath at 75 rpm, maintained at 37 C, for
30 min to ensure complete gelation had taken place. 1 ml
of pre-warmed phosphate-buffered saline (PBS) (pH 7.4)
was added to the gel. At predetermined timepoints (4 h and
day 1, 2, 3, 5, 7, 10, 14, 21 and 28), PBS was completely
removed from the glass vial and the weight of the hydrogel ? glass vial was recorded. After weighing, 1 ml of
fresh pre-warmed PBS was added to the glass vial. All
experiments were carried out in triplicate, for three independent batches. Results are represented as the mean of
three independent experiments ± SEM (n = 3).
Chemotherapeutic Release Studies
1 g of drug-loaded radiopaque thermoresponsive hydrogel
containing 9.22% w/w iodixanol was added to a glass vial
and submerged in a shaking water bath at 75 rpm, maintained at 37 C, for 30 min to ensure complete gelation had
taken place. 1 ml of pre-warmed PBS (pH 7.4) was added

Fig. 1 Representative image of
injectability testing using a
Zwick mechanical testing
machine
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Table 1 Summary of medical
devices used in injectability
testing of various
thermoresponsive hydrogel
formulations

Medical device

Needle gauge (G)/catheter diameter (Fr)

Cook medical needle

18 G

7

Cook medical needle

18 G

20

Chiba biopsy needle

20 G

10

Terumo spinal needle

23 G

9

5 Fr

65

Cordis catheter

to the gelled hydrogel, and at predetermined timepoints
(4 h and day 1, 2, 3, 5, 7, 10, 14, 21 and 28) PBS was
completely removed from the glass vial and then replaced
with 1 ml of fresh pre-warmed PBS. Samples were transferred to a centrifuge tube and stored at - 20 C until
analysis. Analysis of released paclitaxel was performed
using liquid chromatography (Agilent Technologies 1120
Compact LC, CA, USA) with a UV detector, based on a
method by Kraitzer et al. [20]. The mobile phase was
water/acetonitrile (45:55), with a flow rate of 1 ml/min, a
run-time of 10 min and detection at 227 nm. Analysis of
released cisplatin was performed by quantifying platinum
using inductively coupled plasma optical emission spectrometry (Liberty 150 ICP-MS, Varian Inc., CA, USA) at a
detection wavelength of 214.423 nm, with a plasma flow of
15 L/min, auxiliary flow 1.5 L/min and nebulizer pressure
of 200 kPa. All experiments were carried out in triplicate,
for three independent batches. Results are represented as
the mean of three independent experiments ± SEM
(n = 3).

Results
Impact of Iodixanol on Sol–Gel Transition
of Hydrogel Formulations
Figure 2a shows the effect of increasing concentrations of
iodixanol on the material characteristics of the hydrogel.
The storage modulus (G0 ) is the elastic component of the
hydrogel, which is a measure of structure within the
hydrogel. The sol–gel phase transition was marked by an
abrupt increase in the G’ of the gel, indicating a transition
from liquid to semi-solid state at physiological temperatures as observed in Fig. 2b. Concentrations of iodixanol
up to 9.22% w/w did not significantly impact on either the
sol–gel transition temperature or the strength of the
hydrogel. However, increasing the iodixanol concentration
to 13.83% w/w caused a significant reduction in sol–gel
transition temperature and an increase in the strength of the
hydrogel.
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Radiopacity of Iodixanol-Labelled Hydrogel
Formulations
The addition of iodixanol solution to the hydrogel formulation was seen to produce a homogenous gelled formulation at all concentrations evaluated, as evidenced by CT
imaging (Table 2). Addition of iodixanol solution resulted
in increased radiopacity in a concentration-dependent
manner. Gelation only minimally reduced radiopacity in all
three iodixanol-labelled hydrogel groups. Due to favourable rheological and radiopacity characteristics, the
hydrogel containing 9.22% w/w iodixanol was selected for
further assessment.
Distribution of Iodixanol-Labelled Hydrogel in Ex
Vivo Animal Tissue
Injection into ex vivo calves tissue (liver) demonstrated
that the radiopaque thermoresponsive hydrogel (9.22%
w/w iodixanol) was readily injectable, and moulded to the
shape of the target tissue. On US, it was found to be clearly
visualised, anechoic and without speckling (Fig. 3a). It
demonstrated excellent radiopacity on CT achieving
Hounsfield units far in excesses of liver parenchyma even
with the lowest strength formulations (as outlined in
Table 2). The hydrogel was seen to pool in parenchyma
around the needle tip at commencement of injection, and as
resistance (and presumably interstitial pressures) increased,
the thermoresponsive hydrogel formulation subsequently
began to spread along vascular and biliary channels before
undergoing gelation. Following gelation, the thermoresponsive hydrogel moulded to the shape of the tissue,
without further spread indicating successful transition from
liquid to semi-solid had occurred (Fig. 3c–e).
Injectability of Hydrogel Formulations
Rheological measurement of viscosity at 20 C demonstrated shear thinning, i.e. a decrease in viscosity with
increasing shear, which is beneficial for injectability
(Fig. 4a). Radiopaque hydrogel was injectable across all
needle gauges evaluated, with only the 23 G device
required a force greater than 50 N to achieve injection
(Fig. 4b). Injection through a 65-cm 5-Fr catheter was also
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Fig. 2 a Addition of iodixanol
to the hydrogel formulation
impacts the rheological
properties of the
thermoresponsive hydrogel in a
concentration-dependant
manner. Rheogram of the
oscillatory temperature sweeps
from 20 to 40 C of hydrogel
formulations containing
different concentrations of
iodixanol solution.
b Representative image of
hydrogel formulation at room
temperature, in liquid state, and
following incubation at 37 C,
in gelled state. Hydrogel
contains colouring for clarity

shown to be feasible. A force of 0–10 N was considered to
correspond to an injection process which would be ‘‘easy to
inject by hand’’, and injections which require forces up to
50 N to complete can be defined as ‘‘injectable by hand’’
[21].
Disintegration and Chemotherapeutic Release
from Hydrogel Formulations
Similar disintegration profiles for both the blank and drugloaded radiopaque thermoresponsive hydrogel were
observed in vitro over 28 days (Fig. 5a), with both formulations demonstrating extended disintegration profiles.
An initial decrease in mass was observed for both formulations after 4 h of exposure with a subsequent steady
decrease in mass observed thereafter until 168 h, after
which mass loss levelled off, with approx. 20% of the
hydrogel still present at day 28. It is hypothesised that
cross-linking occurring between components of the gel
after transitioning to a gel at 37 C contributes to the
extended disintegration profile of the gel. A slow disintegration of the hydrogel is important to ensure it remains
in situ for a sufficient period of time to enable the
chemotherapeutic drug load to be released at the required
site of action. In vitro release study of a dual drug-loaded
hydrogel showed sustained release of cisplatin and paclitaxel for up to 7 days (Fig. 5b). A significant burst release
of both chemotherapeutic agents was observed in the first
24 h, with a higher burst and shorter sustained release of
cisplatin. This is to be expected as cisplatin has significantly higher water solubility than paclitaxel and therefore

will diffuse more rapidly into the surrounding aqueous
medium driven by simple diffusion. Paclitaxel, with lower
water solubility, showed a smaller burst release and a more
sustained release profile for up to 7 days from the hydrogel.
The rate of drug release from hydrogels has been attributed
to chemical, physical and biological interactions between
the hydrogel matrix, the drugs loaded and surrounding
tissue, including the rate of gel disintegration [22].

Discussion
Thermoresponsive hydrogels can support the delivery of a
range of chemotherapeutic agents, achieving high, and
lasting, local concentrations [3, 23–25]. To transition to
such clinical use however, these hydrogels must be both
easily visible on imaging, and hand injectable. This study
demonstrates that combining an off-the-shelf iodinated
contrast preparation with a novel thermoresponsive
hydrogel formulation is feasible and leads to a clearly
visible formulation both radiographically (on CT) and
sonographically (on US). Furthermore, testing of viscosity
and injectability demonstrates these formulations are
injectable with forces that can be generated by hand. Preliminary in vitro disintegration studies suggest that the
hydrogel has a prolonged disintegration profile, which
would indicate the potential for prolonged retention within
tissue. However, the effect of biological fluid may considerably alter the disintegration profile; therefore, this will
require further in vivo evaluation. Assuming that prolonged
retention is achievable this offers the potential for sustained
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Table 2 Radiopacity of the thermoresponsive hydrogel formulations with increasing concentrations of iodixanol
Liquid (HU)
9.22% w/w iodixanol solution

Thermoresponsive hydrogel with 0% w/w
iodixanol

1523.7 ± 7.09

33.57 ± 2.34

Gelled (HU)

Coronal image of well plate on CT (window width 1488,
level 346)

N/A

22.4 ± 2.06

Thermoresponsive hydrogel with 4.61% w/w
iodixanol

900.03 ± 5.15

697.11 ± 19.28

Thermoresponsive hydrogel with 9.22% w/w
iodixanol

1666.23 ± 6.98

1586.0 ± 12.03

Thermoresponsive hydrogel with 13.83% w/w
iodixanol

2428.83 ± 19.01

2378.7 ± 13.9

Data shown are representative of the mean ± SEM (n = 3)
HU Hounsfield units, w/w weight by weight

drug release, as drug release from a 3D matrix is a function
of diffusion and erosion. These results suggest that the
inherent properties of this thermoresponsive hydrogel offer
potential for transition to the interventional radiology suite
and future treatment opportunities. This is particularly
promising for infiltrative tumours which can be accessed
radiologically and demonstrate response to chemotherapy,
but are not amenable to ablation or resection due to adjacent vital structures. Potential applications would therefore
include
locally
advanced
pancreatic
cancer,
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cholangiocarcinoma, glioblastoma, and infiltrating mediastinal or peritoneal tumours.
The primary limitation of this study is its experimental
nature. While demonstrating that contrast-labelled
chemotherapy-labelled hydrogel can be injected under
image guidance in ex vivo animal liver, translation into
in vivo experimentation and clinical usage still requires
much investigative work. In terms of clinical translation,
further study is required to establish how thermoresponsive
hydrogels behave on delivery into a variety of tissue types
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Fig. 3 Ex vivo tissue administration of the radiopaque thermoresponsive hydrogel can be visualised using CT and US. Representative
a, b US and c, d CT images of radiopaque hydrogel distribution in

ex vivo tissue and e CT images of radiopaque hydrogel pooling at
parenchymal injection site (arrow), following which it spreads
through vascular and biliary channels

and tumour types, in particular their in vivo disintegration
profile. It will also be important to establish any toxicity
associated with the use of the hydrogel. Work is currently
ongoing in a number of pre-clinical xenograft cancer
models to establish efficacy of both the blank and
chemotherapeutic-loaded thermoresponsive hydrogel, and
to determine whether there is any local or systemic toxicity
associated with the hydrogel. The interventional radiologist
will also require an understanding of how these hydrogels
behave in soft tissue. In practice, injection force and spread
within various tumours and organs (and even organs in
various states such as cirrhosis) can feel different. In this
study, the investigators note that within calf liver, the

hydrogel pooled at the needle tip following hand injection,
and flowed into vascular and biliary channels as injection
pressure and volume increased. This would need to be
validated in human tissue and for each clinical indication.

Conclusion
Thermoresponsive hydrogels can be designed to transition
from an injectable liquid at room temperature, to a semisolid at body temperature. This study demonstrates that this
proprietary hydrogel can be loaded with various concentrations of iodinated contrast and chemotherapeutic agents

123

296

A Custom Radiopaque Thermoresponsive Chemotherapy-Loaded Hydrogel for Intratumoural Injection…

Fig. 4 a Unlabelled and contrast-labelled thermoresponsive hydrogel
underwent shear thinning (a decrease in viscosity in response to
increasing shear rate). Data shown is representative of the norm.
b Injectability of radiopaque thermoresponsive hydrogel formulation

at 2 ml/min. Increasing needle gauge and catheter length increases
force required for injection. *p \ 0.05, **p \ 0.01, ***p \ 0.001
compared to Cook needle 18 G 7 cm. Data shown are represented as
the mean ± SEM (n = 3)

Fig. 5 a Disintegration of the blank and drug-loaded radiopaque
thermoresponsive hydrogel over 28 days. Disintegration determined
by measuring loss in mass (% of original weight of hydrogel) per
timepoint. b Cisplatin (measured as platinum) and paclitaxel were
released in a controlled manner from the drug-loaded radiopaque

thermoresponsive hydrogel over a 10 day period. Cumulative
percentage of loaded cisplatin and paclitaxel released over a 10-day
period (240 h). Data shown are representative of the mean of three
independent experiments ± SEM (n = 3)

while maintaining its inherent thermoresponsive properties.
Furthermore, the contrast-labelled thermoresponsive
hydrogel is clearly visualised on a variety of in-use medical
imaging modalities. The viscosity properties of the thermoresponsive hydrogels at room temperature permits hand
injection through off-the-shelf needles and catheters. The
hydrogel demonstrates a slow disintegration profile in vitro
when held at body temperature, with concomitant sustained
drug release. It is important to note that in vitro experiments were performed in a non-biological environment,
and in vivo investigations are required to determine the
disintegration profile and clinical efficacy of the thermoresponsive hydrogel. Preliminary in vitro characteristics
suggest this novel thermoresponsive hydrogel may be

suitable for application in locoregional drug delivery to
solid tumours under image guidance.
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